LA JOLLA, Calif.–(BW HealthWire)–June 25, 2002–Aethlon Medical Inc. (OTCBB:AEMD – News) announced today that a scientific paper authored by R. H. Tullis, R.P. Duffin, M. Zech, and J. A. Ambrus, Jr., entitled “Affinity Hemodialysis for Antiviral Therapy.

 The Removal of HIV-1 from Cell Culture Supernatants, Plasma, and Blood,” was published in the latest issue (Vol. 6, No. 3, 2002) of THERAPEUTIC APHERESIS, The Official Journal of the International Society for Apheresis. The paper discusses the testing of Aethlon Medical’s novel affinity dialysis cartridge to remove HIV from cell culture fluids, plasma and from HIV-infected blood.

 Testing data documented that HIV from infected blood samples was captured with as great or greater efficiency than that of corresponding tests in cell culture fluid or plasma with 83 percent to 100 percent removal in an overnight dialysis. The paper then describes the Aethlon Medical technology as a device that augments the function of the immune system through the physical removal of viruses and toxic proteins from the blood of infected patients. Physical removal of pathogens is precisely what biology accomplishes through humoral and cellular immune response. The device is a modified hemodialysis cartridge containing immobilized antibodies designed to replace or be used in a series with a standard dialysis cartridge. Because antibodies and other elements are covalently bound within the cartridge, minimal side effects may be expected.

לכתבה המלאה